These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 10281256)

  • 21. Hospital drug therapy cost containment through a preferred medicines list and drug utilisation review system.
    Pearce MJ; Begg EJ
    N Z Med J; 1994 Mar; 107(974):101-4. PubMed ID: 8127505
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cefoxitin use review.
    Lazor-Bajcar JM
    Can J Hosp Pharm; 1990 Oct; 43(5):221-5, xxxii. PubMed ID: 10107924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metronidazole cost containment: a two-stage intervention.
    Bunz D; Gupta S; Jewesson P
    Hosp Formul; 1990 Nov; 25(11):1167-9, 1177. PubMed ID: 10107821
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ciprofloxacin use under a reserved drug and stepdown promotion program.
    Frighetto L; Martinusen SM; Mamdani F; Jewesson PJ
    Can J Hosp Pharm; 1995 Feb; 48(1):35-42. PubMed ID: 10141061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of clinical pharmacists to reduce cefamandole, cefoxitin, and ticarcillin costs.
    Abramowitz PW; Nold EG; Hatfield SM
    Am J Hosp Pharm; 1982 Jul; 39(7):1176-80. PubMed ID: 7114059
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Computer program for comparing total costs of intravenous antibiotic regimens.
    Parr MD; Hansen LA; Waite WW; Rapp RP
    Am J Hosp Pharm; 1986 Sep; 43(9):2189-93. PubMed ID: 3766570
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Controlling moxalactam and cefotaxime use with a target drug program.
    Abramowitz PW; Ludwig DJ; Mansur JM; Nold EG
    Hosp Pharm; 1983 Aug; 18(8):416-20. PubMed ID: 10261791
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative cost effectiveness of gentamicin and tobramycin.
    Holloway JJ; Smith CR; Moore RD; Feroli ER; Lietman PS
    Ann Intern Med; 1984 Dec; 101(6):764-9. PubMed ID: 6437310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of a practical two-stage intervention on aminoglycoside usage.
    Shalansky S; Gupta S; Jewesson P
    Hosp Formul; 1989 Jun; 24(6):332-6, 339-41. PubMed ID: 10293282
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic interchange of cefazolin with metronidazole for cefoxitin.
    Brown GR; Clarke AM
    Am J Hosp Pharm; 1992 Aug; 49(8):1946-50. PubMed ID: 1442838
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of a pharmacy-based cost-containment program on cimetidine costs and use.
    Kong KM; Johnson WF; Anderson PO; Sato LA; Simonian RI
    Am J Hosp Pharm; 1987 Sep; 44(9):2068-73. PubMed ID: 3674045
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Experience with a once-daily dosing program of aminoglycosides in critically ill patients.
    Buijk SE; Mouton JW; Gyssens IC; Verbrugh HA; Bruining HA
    Intensive Care Med; 2002 Jul; 28(7):936-42. PubMed ID: 12122533
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aminoglycoside utilization study.
    Haslett TM; Reynolds JR
    Hosp Pharm; 1988 Oct; 23(10):872, 874-5, 878-80. PubMed ID: 10290108
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of antibiotic order form guiding rational use of expensive drugs on cost containment.
    Sirinavin S; Suvanakoot P; Sathapatayavongs B; Malatham K
    Southeast Asian J Trop Med Public Health; 1998 Sep; 29(3):636-42. PubMed ID: 10437971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A targeted review of vancomycin use.
    Piquette RK
    Can J Hosp Pharm; 1991 Apr; 44(2):83-7. PubMed ID: 10111726
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A strategy to reduce drug expenditures with a drug utilization review program.
    Hoffmann RP
    Hosp Pharm; 1984 Jan; 19(1):7-8, 11-2. PubMed ID: 10264746
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of the Hospital Pharmacy Initiative for promoting prudent use of antibiotics in hospitals in England.
    Wickens HJ; Jacklin A
    J Antimicrob Chemother; 2006 Dec; 58(6):1230-7. PubMed ID: 17030518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A commentary on high-cost drugs.
    de Leon RF
    Curr Concepts Hosp Pharm Manage; 1989; 11(3):4-7. PubMed ID: 10318277
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost savings from dose rounding of biologic anticancer agents in adults.
    Winger BJ; Clements EA; DeYoung JL; O'Rourke TJ; Claypool DL; Vachon S; VanDyke TH; Zimmer-Young J; Kintzel PE
    J Oncol Pharm Pract; 2011 Sep; 17(3):246-51. PubMed ID: 20332175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacy-laboratory interactions: a unique method to control antibiotic costs.
    Goff D; Thornton J
    Hosp Pharm; 1989 Jan; 24(1):26-9, 32. PubMed ID: 10291600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.